Board of Directors

Election to the Board

Harry Hyman founded the Company in 1996 and served on the Board as Managing Director from that time and represented the former adviser to the Company, Nexus Tradeco Limited (“Nexus”), on the Board. On completion of the management internalisation on 5 January 2021, Harry was appointed as Chief Executive Officer. He was appointed as Non-executive Chair with effect from the end of the 2024 AGM, following the appointment of Mark Davies as Chief Executive. He stepped down as Chair of the Nomination Committee in December 2025.

Harry graduated from Cambridge University and trained as a Chartered Accountant and Corporate Treasurer. He is a Fellow of the Institute of Chartered Accountants in England and Wales.

Skills, competence and experience

Harry has significant and extensive experience in investing in the primary healthcare sector, having developed the Company’s business from its inception 30 years ago to its current position.

He brings leadership experience as Chair of another listed company and entrepreneurial flair to the Board having established a number of successful private companies. Harry was key to the successful Assura transaction.

Other listed company directorships

Non-executive Chair of Biopharma Credit PLC, an externally managed investment trust which invests in the fast-growing science industry and is listed on the London Stock Exchange.

Election to the Board

Mark Davies was appointed to the Board from the 2024 AGM.

Career

Mark was a Co-founder Director of NewRiver REIT plc (“NewRiver”) in 2009 and played an important role in taking NewRiver from IPO into the FTSE 250 Index in seven years. He was CFO of NewRiver for over twelve years and, alongside his role as CFO, was also CEO/Executive Chair of Hawthorn Leisure Limited (“Hawthorn”) for five years. Mark stood down from the board of NewRiver following the successful sale of Hawthorn in July 2021 to private equity at a premium price.

Skills, competence and experience

Mark has considerable capital markets, listed company leadership and entrepreneurial experience and was key to the successful Assura transaction.

Other listed company directorships

None.

Election to the Board

Richard Howell was appointed to the Board from 31 March 2017. He was appointed as Chief Financial Officer in 2021 following completion of the internalisation of the advisory and management functions previously carried out by Nexus.

Career

Richard is a Chartered Accountant and has over 20 years’ experience working with London-listed commercial property companies, principally LondonMetric Property plc and Brixton plc. Richard was part of the senior management team that led the merger of Metric Property Investments plc and London & Stamford Property plc in 2013 to create LondonMetric Property plc. In May 2022 he was appointed as a Non-executive Director at Life Science REIT plc, an AIM-listed, externally managed real estate investment trust.

Skills, competence and experience

Richard has extensive finance and accounting experience, having previously held senior accounting positions within listed property companies operating across the UK. This experience includes both equity and debt financing for the acquisition of Assura, together with implementing the Company’s hedging strategy. Richard has been responsible for arranging and negotiating lending arrangements for the Company and in previous roles with major UK banking and finance institutions and advisors, including at LondonMetric Property plc and Brixton plc, leading the finance teams in over £5 billion of property transactions.

Other listed company directorships

Senior Independent Non-executive Director and Chair of the Audit Committee of Life Science REIT plc.

Election to the Board

Laure Duhot was appointed to the Board from 14 March 2019 following completion of the merger with MedicX Fund Limited.

Career

Laure started her career in the investment banking sector and has developed a focus on the property and infrastructure sectors. She has held senior roles at Lehman Brothers, Macquarie Capital Partners, Sunrise Senior Living Inc., Grainger plc and Lendlease.

Skills, competence and experience

Laure brings over 30 years of senior executive level experience in the investment banking and property sectors, specialising in alternative real estate assets, and has been a Non-executive Director at a number of funds and property companies.

Other listed company directorships

Safestore Holdings plc

Independent Non-executive

Yes.

Election to the Board

Ian Krieger was appointed to the Board in February 2018, and is Chair of the Audit Committee.

Career

Ian is a Chartered Accountant and was a Partner and Vice-Chair at Deloitte until his retirement in 2012.

Skills, competence and experience

Ian qualified as and practised as a Chartered Accountant and brings a wealth of recent financial experience to the Board as well as his experience as Chair of the audit committees of two other UK-listed companies in the property sector (having been Senior Independent Non-executive Director and Chair of the audit committee at both Safestore Holdings plc and Capital & Regional plc until his retirement in 2024).

Other listed company directorships

None.

Independent Non-executive

Yes.

Election to the Board

Ivonne Cantú was appointed to the Board from 1 January 2022.

Career

Ivonne has significant public company experience having spent over 20 years advising listed businesses. She was until 31 August 2025 the Director of Investor Relations, Communications and Sustainability as well as a member of the executive management team of Benchmark Holdings plc, a biotechnology aquaculture company. She is also a Non-executive Director and Chair of the audit committee at Creo Medical Group plc and a Trustee of two non-profit UK based charities, La Vida - Vital Investment for Development Aid in Latin America and Info Latinos.

Skills, competence and experience

Ivonne brings to the Board substantial experience in capital markets, M&A, corporate governance, investor relations and sustainability. Prior to taking up her position at Benchmark Holdings plc, Ivonne spent 13 years as Corporate Finance Adviser at Cenkos Securities plc and Merrill Lynch, advising companies across multiple sectors and geographies. She has a degree in engineering from the Universidad Panamericana in Mexico City and an MBA from the Wharton School of Business at the University of Pennsylvania.

Other listed company directorships

Creo Medical Group plc.

Independent Non-executive

Yes.

Election to the Board

Bina Rawal was appointed to the Board from 27 February 2024.

Career

Bina is a medical professional with 25 years’ senior executive experience in healthcare, including with blue chip pharmaceutical companies such as Roche and global research funding charity Wellcome Trust. She is currently Senior Independent Director at Worldwide Healthcare Trust plc, a FTSE 250-listed investment trust specialising in healthcare and life sciences companies where she is board lead for ESG and chairs the nominations committee.

Skills, competence and experience

Bina has a wide breadth of experience spanning patient care, digital and population health, ESG, strategy, partnerships and EDI, alongside extensive networks in UK healthcare through her senior level executive and non-executive roles to date in large, complex organisations within the public, private and not-for-profit sectors.

Other listed company directorships

Worldwide Healthcare Trust plc.

Independent Non-executive

Yes.

Election to the Board

Jonathan Davies was appointed to the Board from 1 December 2025.

Career

Jonathan was until recently Chief Financial Officer of SSP Group plc (“SSP”), where he also served as Deputy Chief Executive. Since his appointment in June 2018, Jonathan also served as a Non-Executive Director of Assura plc (“Assura”) until the clearance of the Company’s acquisition of Assura by the Competition and Markets Authority on 29 October 2025. His skills in strategy, commercial and financial management were built in his earlier roles with Unilever plc, OC&C and Safeway plc.

Skills, competence and experience

Jonathan brings to the Board extensive experience of finance, mergers and acquisitions and corporate governance, having taken SSP private in 2006, listed it on the London Stock Exchange in 2014 and undertaken numerous debt and equity raises since then. Jonathan also brings a deep understanding of Assura, having served as its Senior Independent Director, Chair of the Audit Committee and, latterly, Chair, providing stakeholders with continuity during the integration period and beyond.

Other listed company directorships

None.

Independent Non-executive

Yes.